EGFR and non-small cell lung carcinoma: Based on the findings of the FLAURA trial, which showed significantly prolonged progression‐free survival (PFS) and overall survival (OS) in the osimertinib arm compared to that in the standard treatment arm (median PFS: 18.9 months [95% confidence interval or CI, 15.2–21.4] vs. 10.2 months [95% CI, 9.6–11.1]; hazard ratio [HR], 0.46; p < 0.001; median OS: 38.6 months [95% CI, 34.5–41.8] vs. 31.8 months [95% CI, 26.6–36.0]; HR, 0.80; p < 0.05) [3, 4], osimertinib is now considered as the standard treatment agent for advanced EGFR‐positive NSCLC patients.